Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9126570 | 0.83 | MIF (0.33) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL8761432 | 0.80 | STAT3 (0.44) | — | |
| SCHEMBL412107 | 0.80 | HDAC6 (0.36) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| Hydrochloric Acid SCHEMBL439920 | 0.78 | HDAC6 (0.35) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21634141 | 0.78 | HDAC6 (0.34) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL2308502 | 0.78 | MIF (0.34) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL478959 | 0.78 | CNR2 (0.33) | — | |
| SCHEMBL8233965 | 0.78 | HDAC4 (0.39) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL989859 | 0.77 | HDAC6 (0.34) | MIFHDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL13189194 | 0.75 | MIF (0.35) | MIFHDAC6HDAC1HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-3080125-B1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-10-10 | — | — | EP | disclosed |
| CN-105940001-B | Alternatively the new 7-azaindole derivatives of property histone deacetylase (HDAC) inhibitor and include its pharmaceutical composition | 株式会社钟根堂 | 2018-02-06 | — | — | CN | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| EP-3080125-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-19 | — | — | EP | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| WO-2015087151-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | WO | disclosed |
| EP-0590415-B1 | 1,2,4-Oxadiazole derivatives for controlling endoparasites | BAYER AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| US-5428047-A | Nematocides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-06-27 | — | — | US | disclosed |
| EP-0590415-A2 | 1,2,4-Oxadiazole derivatives for controlling endoparasites | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MIF 4268/4885HDAC6 634/4885HDAC1 271/4885 |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC5, HDAC1, HDAC2 | MIF 1657/4885HDAC6 4/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.